X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-04 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale | $106.03 | -6,628 | 125,537 | -5% | -$702,744 | |||||
| D | 2026-02-06 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | CEO | S - Sale+OE | $20.62 | -7,412 | 508,849 | -1% | -$152,835 | |||||
| D | 2026-02-06 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale+OE | $20.62 | -2,082 | 143,839 | -1% | -$42,931 | |||||
| D | 2026-02-04 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $349.52 | -1,660 | 223,106 | -1% | -$580,197 | |||||
| D | 2026-02-06 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Dir | S - Sale+OE | $83.68 | -20,000 | 7,825 | -72% | -$1,673,600 | |||||
| D | 2026-02-06 | MRK | Merck & Co., Inc. | Williams David Michael | EVP,Chief Info, Digital Office | S - Sale+OE | $121.91 | -5,000 | 30,838 | -14% | -$609,525 | |||||
2026-02-05 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale | $152.44 | -869 | 83,243 | -1% | -$132,470 | ||||||
| D | 2026-02-04 | MRK | Merck & Co., Inc. | Smart Dalton E. III | SVP Fin. - Global Controller | S - Sale+OE | $119.68 | -6,400 | 8,205 | -44% | -$765,920 | |||||
2026-02-06 | MRK | Merck & Co., Inc. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale | $121.87 | -15,000 | 21,197 | -41% | -$1,827,992 | ||||||
| D | 2026-02-04 | MRK | Merck & Co., Inc. | Litchfield Caroline | EVP, CFO | S - Sale+OE | $119.61 | -41,997 | 90,192 | -32% | -$5,023,312 | |||||
| D | 2026-02-04 | MRK | Merck & Co., Inc. | Li Dean Y | EVP, Pres, MRL | S - Sale+OE | $118.77 | -15,087 | 102,270 | -13% | -$1,791,824 | |||||
2026-02-05 | MRK | Merck & Co., Inc. | Guindo Chirfi | CMO | S - Sale | $121.88 | -20,000 | 80,615 | -20% | -$2,437,676 | ||||||
2026-02-06 | MRK | Merck & Co., Inc. | Deluca Richard R. | EVP, Pres, Merck Animal Heallt | S - Sale | $120.92 | -37,685 | 160,174 | -19% | -$4,557,025 | ||||||
2026-02-04 | MRK | Merck & Co., Inc. | Davis Robert M | COB, CEO, Pres | S - Sale | $118.05 | -47,434 | 443,602 | -10% | -$5,599,327 | ||||||
2026-02-04 | ABT | Abbott Laboratories | Starks Daniel J | Dir | P - Purchase | $108.73 | +10,000 | 6,739,075 | 0% | +$1,087,331 | ||||||
| D | 2026-02-05 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $61.93 | -15,000 | 50,440 | -23% | -$928,950 | |||||
| DM | 2026-02-03 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $41.39 | -13,180 | 65,640 | -17% | -$545,473 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Coric Vlad | Dir | P - Purchase | $17.00 | +117,646 | 449,337 | +35% | +$1,999,982 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Childs John W | Dir | P - Purchase | $17.00 | +294,117 | 2,202,006 | +15% | +$4,999,989 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Longitude Capital Partners V, LLC | 10% | P - Purchase | $17.00 | +1,075,000 | 2,053,474 | +110% | +$18,275,000 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Enright Patrick G | Dir, 10% | P - Purchase | $17.00 | +1,075,000 | 2,053,474 | +110% | +$18,275,000 | |||||
| D | 2026-02-03 | PMN | Promis Neurosciences Inc. | Abg Management Ltd. | 10% | P - Purchase | $12.13 | +700,741 | 943,090 | +289% | +$8,499,988 | |||||
| D | 2026-02-03 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $40.87 | -20,000 | 1,235 | -94% | -$817,334 | |||||
| D | 2026-02-05 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $483.25 | -8,300 | 36,781 | -18% | -$4,010,940 | |||||
2026-02-03 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale | $14.94 | -4,170 | 162,894 | -2% | -$62,305 | ||||||
2026-02-04 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $6.69 | -970 | 612,919 | 0% | -$6,489 | ||||||
2026-02-04 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Chief Medical Officer | S - Sale | $32.21 | -1,779 | 105,706 | -2% | -$57,295 | ||||||
2026-02-04 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $32.19 | -1,745 | 111,226 | -2% | -$56,168 | ||||||
2026-02-04 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale | $32.18 | -2,994 | 105,211 | -3% | -$96,359 | ||||||
2026-02-03 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $4.10 | -5,559 | 550,000 | -1% | -$22,792 | ||||||
| DM | 2026-02-02 | SPRO | Spero Therapeutics, Inc. | Keutzer Timothy | COO | S - Sale+OE | $2.17 | -46,586 | 761,158 | -6% | -$101,175 | |||||
| D | 2026-02-02 | SPRO | Spero Therapeutics, Inc. | Rajavelu Esther | See Remarks | S - Sale+OE | $2.20 | -18,442 | 1,100,008 | -2% | -$40,572 | |||||
2026-02-02 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $32.80 | -15,000 | 657,540 | -2% | -$492,045 | ||||||
| M | 2026-02-02 | MPLT | Maplight Therapeutics, Inc. | Malenka Robert C. | Dir | S - Sale | $18.02 | -7,040 | 389,905 | -2% | -$126,861 | |||||
2026-02-02 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $25.28 | -40,638 | 110,003 | -27% | -$1,027,293 | ||||||
| M | 2026-02-02 | ZNTL | Zentalis Pharmaceuticals, Inc. | Vultaggio Vincent | PAO, PFO | S - Sale | $2.54 | -3,096 | 186,730 | -2% | -$7,875 | |||||
| M | 2026-02-02 | OCUL | Ocular Therapeutix, Inc | Notman Donald | COO | S - Sale | $8.82 | -11,490 | 377,802 | -3% | -$101,398 | |||||
| D | 2026-02-03 | TNGX | Tango Therapeutics, Inc. | Beckman Daniella | CFO | S - Sale+OE | $12.26 | -10,317 | 184,297 | -5% | -$126,531 | |||||
| D | 2026-02-03 | TNGX | Tango Therapeutics, Inc. | Weber Barbara | Dir, Exec Chair | S - Sale+OE | $12.26 | -30,519 | 1,629,254 | -2% | -$374,294 | |||||
| D | 2026-02-03 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $12.26 | -18,452 | 187,218 | -9% | -$226,300 | |||||
| M | 2026-02-02 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.58 | -30,953 | 3,530,702 | -1% | -$1,379,866 | |||||
| M | 2026-02-02 | SION | Sionna Therapeutics, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $44.58 | -30,953 | 3,530,702 | -1% | -$1,379,866 | |||||
2026-02-03 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale | $19.69 | -7,373 | 144,985 | -5% | -$145,174 | ||||||
| M | 2026-02-02 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $25.72 | -13,469 | 80,651 | -14% | -$346,455 | |||||
2026-02-02 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale | $25.50 | -19,833 | 954,440 | -2% | -$505,710 | ||||||
2026-02-02 | ARQT | Arcutis Biotherapeutics, Inc. | Vairavan Latha | SVP CFO | S - Sale | $25.50 | -1,320 | 63,607 | -2% | -$33,658 | ||||||
2026-02-02 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $25.05 | -10,000 | 59,744 | -14% | -$250,483 | ||||||
2026-02-02 | ARQT | Arcutis Biotherapeutics, Inc. | Edwards Larry Todd | See Remarks | S - Sale | $25.50 | -2,052 | 148,865 | -1% | -$52,323 | ||||||
| DM | 2026-02-02 | KNSA | Kiniksa Pharmaceuticals International, Plc | Quart Barry D | Dir | S - Sale+OE | $45.22 | -15,960 | 12,546 | -56% | -$721,635 | |||||
2026-02-02 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $195.91 | -467 | 43,187 | -1% | -$91,490 | ||||||
| M | 2026-02-02 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $42.54 | -243,541 | 237,855 | -51% | -$10,360,814 | |||||
| D | 2025-12-05 | BOLT | Bolt Biotherapeutics, Inc. | Quinn William P. | Pres, CEO, CFO | P - Purchase | $4.61 | +125 | 2,313 | +6% | +$576 | |||||
| D | 2025-12-05 | BOLT | Bolt Biotherapeutics, Inc. | Nemec Sarah | SVP, Finance, PAO | P - Purchase | $4.61 | +125 | 1,415 | +10% | +$576 | |||||
2026-02-02 | ABEO | Abeona Therapeutics Inc. | Silverstein Christine Berni | Dir | S - Sale | $5.09 | -20,070 | 137,722 | -13% | -$102,168 | ||||||
2026-02-03 | ZVRA | Zevra Therapeutics, Inc. | Sangiovanni Timothy J. | SVP, Finance, Corp Controller | S - Sale | $9.18 | -3,000 | 29,590 | -9% | -$27,548 | ||||||
2026-02-03 | ZVRA | Zevra Therapeutics, Inc. | Schafer Joshua | CCO | S - Sale | $9.19 | -10,500 | 62,278 | -14% | -$96,500 | ||||||
2026-02-03 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Smethurst Dominic | Chief Medical Officer | S - Sale | $8.09 | -3,285 | 95,887 | -3% | -$26,575 | ||||||
2026-02-02 | LXRX | Lexicon Pharmaceuticals, Inc. | Invus Global Management, LLC | Dir, 10% | P - Purchase | $1.30 | +1,538,462 | 44,145,189 | +4% | +$2,000,001 | ||||||
2026-02-03 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Hodgson Ian | COO | S - Sale | $8.09 | -2,415 | 51,927 | -4% | -$19,537 | ||||||
2026-02-03 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale | $156.17 | -791 | 106,810 | -1% | -$123,530 | ||||||
2026-02-03 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale | $156.34 | -748 | 79,758 | -1% | -$116,942 | ||||||
2026-02-03 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale | $156.34 | -3,009 | 588,306 | -1% | -$470,427 | ||||||
2026-02-02 | ALXO | Alx Oncology Holdings Inc | Goodman Corey S | Dir, 10% | P - Purchase | $1.57 | +3,184,713 | 13,052,008 | +32% | +$4,999,999 | ||||||
2026-02-03 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $156.27 | -640 | 56,397 | -1% | -$100,013 | ||||||
2026-02-02 | AKBA | Akebia Therapeutics, Inc. | Malabre Richard C | SVP, Chief Accounting Officer | S - Sale | $1.39 | -49,524 | 299,390 | -14% | -$68,838 | ||||||
| DM | 2026-02-02 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $154.70 | -8,777 | 84,112 | -9% | -$1,357,796 | |||||
| A | 2026-01-02 | FULC | Fulcrum Therapeutics, Inc. | Gould Robert J | Dir | S - Sale | $10.87 | -15,000 | 469,864 | -3% | -$163,089 | |||||
2026-02-02 | AKBA | Akebia Therapeutics, Inc. | Grund Nicholas | Chief Commercial Officer | S - Sale | $1.39 | -84,829 | 561,750 | -13% | -$117,912 | ||||||
2026-02-02 | AKBA | Akebia Therapeutics, Inc. | Burke Steven Keith | SVP, Chief Medical Officer | S - Sale | $1.39 | -67,658 | 948,432 | -7% | -$94,045 | ||||||
2026-02-02 | AKBA | Akebia Therapeutics, Inc. | Rucci Carolyn M. | SVP, GC | S - Sale | $1.39 | -69,772 | 588,378 | -11% | -$96,983 | ||||||
2026-02-03 | KPTI | Karyopharm Therapeutics Inc. | Macomber Lori | EVP, CFO, Treasurer | S - Sale | $6.30 | -1,626 | 85,105 | -2% | -$10,244 | ||||||
2026-02-02 | AKBA | Akebia Therapeutics, Inc. | Ostrowski Erik | SVP, CFO, CBO, Treasurer | S - Sale | $1.39 | -34,951 | 672,635 | -5% | -$48,582 | ||||||
2026-02-02 | AKBA | Akebia Therapeutics, Inc. | Butler John P. | CEO, Pres | S - Sale | $1.39 | -341,305 | 3,457,722 | -9% | -$474,414 | ||||||
2026-02-02 | FULC | Fulcrum Therapeutics, Inc. | Gould Robert J | Dir | S - Sale | $10.72 | -15,000 | 454,864 | -3% | -$160,857 | ||||||
| D | 2026-02-02 | IONS | Ionis Pharmaceuticals Inc | Bennett C Frank | EVP, Chief Scientific Officer | S - Sale+OE | $82.93 | -85,089 | 80,293 | -51% | -$7,056,216 | |||||
2026-02-02 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $58.00 | +100 | 460,944 | 0% | +$5,800 | ||||||
2026-02-02 | AMLX | Amylyx Pharmaceuticals, Inc. | Frates James M | CFO | S - Sale | $14.65 | -3,557 | 300,078 | -1% | -$52,097 | ||||||
2026-02-02 | AMLX | Amylyx Pharmaceuticals, Inc. | Cohen Joshua B | Co-CEO | S - Sale | $14.68 | -15,500 | 3,363,965 | 0% | -$227,593 | ||||||
2026-02-02 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $14.65 | -3,448 | 144,693 | -2% | -$50,516 | ||||||
2026-02-02 | AMLX | Amylyx Pharmaceuticals, Inc. | Klee Justin B. | Co-CEO | S - Sale | $14.69 | -15,500 | 3,363,898 | 0% | -$227,618 | ||||||
2026-02-02 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Pres, COO | S - Sale | $103.30 | -2,631 | 20,655 | -11% | -$271,792 | ||||||
2026-02-02 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale | $103.30 | -9,108 | 347,794 | -3% | -$940,888 | ||||||
| D | 2026-02-02 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $103.30 | -968 | 4,503 | -18% | -$99,998 | |||||
| D | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO | S - Sale+OE | $32.28 | -100,087 | 432,886 | -19% | -$3,230,316 | |||||
| D | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Chief Medical Officer | S - Sale+OE | $32.12 | -6,956 | 107,485 | -6% | -$223,427 | |||||
| D | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale+OE | $32.12 | -7,242 | 112,971 | -6% | -$232,613 | |||||
| D | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Chief Commercial Officer | S - Sale+OE | $32.12 | -7,310 | 131,823 | -5% | -$234,797 | |||||
| D | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Rote William E. | Chief Research Officer | S - Sale+OE | $32.87 | -12,446 | 109,087 | -10% | -$409,100 | |||||
| D | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, Chief Accounting Officer | S - Sale+OE | $32.12 | -4,333 | 49,080 | -8% | -$139,176 | |||||
| D | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale+OE | $32.12 | -7,175 | 108,205 | -6% | -$230,461 | |||||
| DM | 2026-01-30 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $25.15 | -39,961 | 123,145 | -25% | -$1,004,918 | |||||
2026-02-02 | PCRX | Pacira Biosciences, Inc. | Riker Lauren | SVP, Finance | S - Sale | $20.81 | -4,000 | 52,313 | -7% | -$83,240 | ||||||
2026-02-02 | PCRX | Pacira Biosciences, Inc. | Williams Kristen | Chief Administrative Officer | S - Sale | $20.53 | -13,137 | 131,303 | -9% | -$269,703 | ||||||
2026-02-03 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale | $474.23 | -50 | 270 | -16% | -$23,712 | ||||||
| D | 2026-02-02 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $470.95 | -22,500 | 2,648 | -89% | -$10,596,429 | |||||
2026-02-02 | ZBIO | Zenas Biopharma, Inc. | Moulder Leon O Jr | CEO | P - Purchase | $17.96 | +57,000 | 2,132,122 | +3% | +$1,023,720 | ||||||
| D | 2026-02-02 | BIOA | Bioage Labs, Inc. | Rubin Paul D | Chief Medical Officer | S - Sale+OE | $18.75 | -7,433 | 0 | -100% | -$139,369 | |||||
2025-12-10 | AVBP | Arrivent Biopharma, Inc. | Hillhouse Investment Management, Ltd. | 10% | S - Sale | $23.37 | -555,555 | 3,929,117 | -12% | -$12,983,320 | ||||||
| D | 2026-02-02 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.03 | -6,500 | 0 | -100% | -$19,680 | |||||
2026-02-02 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $23.56 | -3,061 | 88,935 | -3% | -$72,117 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |